Sample Type & Matrix Effects in Lateral Flow Assay Development

In earlier articles in this series, we explored selecting high performing antibodies and optimising detector labels & bioconjugation strategies. These steps are critical to achieving strong analytical performance under controlled conditions.

However, many assays that perform well in initial buffer testing may behave differently when applied to real clinical or environmental samples. Whole blood, saliva, urine, swab extracts, food and other matrices introduce biological variability, chemical interference and physical flow challenges that fundamentally alter assay behaviour.

Early evaluation with the intended sample matrix is therefore essential, allowing developers to tailor assay design and performance to real world samples and avoid unexpected issues later in development.

This article examines how sample characteristics and matrix properties influence assay design, highlights approaches to systematically evaluate variability and outlines risk informed strategies to ensure robust analytical and clinical performance.

Understanding Application and Clinical Relevance

Lateral flow assay development begins with a detailed understanding of the intended application and use. Developers must define the target population, the biological matrix most appropriate for detection and the clinical questions the assay is designed to address. Establishing clinical relevance requires knowledge of expected analyte concentrations across sexes, age groups, disease stages and other relevant subpopulations, as well as potential diurnal or situational fluctuations.

For example, urinary analyte concentrations may vary depending on hydration status or time of day, while salivary biomarkers may be influenced by food intake or oral hygiene. Considering these factors early ensures that the assay is optimised for real world use, not just controlled laboratory conditions.

Practical guidance includes reviewing literature on biomarker distribution and conducting pilot studies with small representative cohorts to confirm expected concentration ranges. Mapping these ranges to the achievable sensitivity of the lateral flow assay before committing to antibody selection or strip design ensures assay development starts from a realistic foundation.

Practical considerations of sample collection, handling and storage should be acknowledged early. Developers must ensure that the sample can be collected consistently in the intended environment and remains stable through transport or storage. These considerations provide context for assay robustness and guide subsequent technical design decisions, which are explored in detail later.

Sample Characterisation and Analyte Considerations

Once the clinical application is defined, the analyte must be characterised within the relevant matrix. Key considerations include its molecular form, molecular weight and whether it exists free, bound to carrier proteins or complexed with other biomolecules.

Understanding these properties informs antibody design, assay format selection and sensitivity requirements, ensuring that target levels fall within the detectable range, typically 0.1–100 ng/mL for lateral flow devices.

Further evaluation of the analyte’s in-matrix presentation and behaviour should include:

• Review published literature, database annotations and existing clinical assay documentation to establish the analyte’s known circulating forms, post-translational modifications, binding partners and reported concentration ranges within the relevant matrix.

• Use multiple candidate antibodies to probe the analyte in its native matrix, verifying that it can be detected under real world conditions, including any modifications, folding or binding interactions that might influence accessibility.

• Evaluating free versus total analyte behaviour, for example by comparing recovery in spiked versus native matrix or through controlled dilution, to determine whether the assay predominantly detects free analyte and whether binding partners might influence signal.

  
  

• Assessing analyte stability under anticipated storage or transport conditions such as room temperature, refrigeration or realistic freeze-thaw cycles.

  
  

• Simple dilution series to assess matrix suppression, comparing neat and serially diluted samples to identify interference, optimise dilution strategies and maintain analyte concentrations within the detectable range.

  
  

• Adjusting buffer formulations, sample treatments or membrane chemistries as needed to maintain analyte integrity and compatibility with the assay.

By incorporating these approaches early, developers can gain practical insight into how the analyte is presented in the intended matrix and how this affects assay performance, without adding significant time, cost or complexity. This knowledge directly informs antibody selection, assay architecture and design mitigation strategies, setting the foundation for robust and reproducible lateral flow assay development.

Matrix Considerations in Lateral Flow Assay Development

Matrix effects arise when the inherent components of a sample influence the behaviour of a lateral flow assay, affecting analyte binding, fluid migration and signal generation. These effects are often complex and non linear, as chemical, biological and physical factors can interact in unpredictable ways. Because each sample matrix presents a unique combination of these factors, the same analyte can behave very differently across donors, time points or sample handling conditions.

Early understanding of these interactions is critical to developing assays that are robust, reproducible and reliable under real-world conditions.

Key manifestations of matrix effects include:

• Non specific protein binding, which increases background signal.

  
  

• Endogenous proteins causing non-specific interference or reducing effective analyte binding.

  
  

• Altered viscosity affecting flow kinetics and analyte delivery.

  
  

• pH variations influencing antibody affinity.

  
  

• Particulates partially obstructing membranes.

Different sample matrices present distinct technical challenges that must be addressed during development:

Whole blood: High viscosity and cellular content influence flow behaviour and signal intensity. Haematocrit variability alters plasma yield and migration, and at elevated haematocrit levels, reduced plasma delivery can impair flow and decrease assay sensitivity. Integrated blood separation membranes and careful volume control help maintain consistent separation and analytical performance. Handling differences between finger-prick capillary blood and venous blood collected with anticoagulants (e.g. EDTA, citrate, or heparin) should also be considered, as these additives may act as assay interferents affecting analyte stability, antibody binding or signal development.

Urine: Analyte concentration, pH and ionic strength fluctuate throughout the day and between donors, influencing antibody binding, signal development and flow characteristics; these can be managed with buffering and controlled sample dilution. Particulate matter, crystallisation (e.g. salts) and microbial contamination may interfere with membrane flow or background signal, but can be mitigated through pre-filters, preservatives and defined storage conditions.

Saliva: Although non-invasive and convenient, saliva exhibits substantial inter-individual variability in viscosity, mucin content, enzyme activity and particulate load, leading to differences in flow behaviour and matrix interference. Controlled dilution (typically 1:1–1:3) is often required to reduce interference and improve consistency, but must be optimised to maintain analyte concentrations within the detectable range.

Swab extracts: 

Matrices such as nasal, nasopharyngeal or wound extracts vary in viscosity, mucus or exudate content, cellular load and pH, all of which can influence flow and signal development. Variability can be controlled through optimised extraction buffer formulations, pre-treatment of samples (e.g. dilution or homogenisation), standardised extraction protocols and consistent handling procedures.

Food or environmental samples: These matrices often have heterogeneous composition, variable particulates, fats, proteins and potential inhibitors, all of which can interfere with flow, binding or signal generation. Accurate and representative sampling is critical; homogenisation of the sample prior to extraction ensures consistent analyte distribution. Pre-treatment strategies such as filtration, centrifugation or selective extraction buffers can reduce particulates and inhibitory components, while surfactants may be used to manage fats and lipids. Standardised extraction protocols and defined sample volumes ensure reproducible recovery and reliable assay performance.

Design and Mitigation Strategies

Robust assay design addresses matrix realities while preserving sensitivity and reproducibility. Key strategies include:

• Controlled dilution: Applied to viscous or protein rich samples, this method reduces matrix interference and is often the simplest solution, though it does introduce additional user processing steps and it must maintain detectable analyte levels.

  
  

• Buffer optimisation: Within complex sample matrices, buffer composition plays a central role in controlling assay behaviour. Surfactants can improve flow characteristics while reducing non specific interactions at membrane and particle surfaces and protein blockers such as BSA help minimise adsorption losses of antibodies and analytes to device materials. Chelating agents, including EDTA, may be introduced to control metal ion dependent interference, while careful adjustment of pH and ionic strength supports stable antibody antigen binding within the matrix environment. In more labile samples, the inclusion of protease inhibitors can be necessary to preserve analyte integrity.

  
  

• Physical device adaptations: Conjugate pad treatments can be optimised to enhance reagent release, particularly for viscous or protein rich samples where flow is slower. Membrane pore size should be selected to match expected sample viscosity and flow behaviour, supporting consistent migration and signal development. Filtration pads may be incorporated to remove particulates from swab, food or environmental matrices, protecting membrane integrity and reducing background interference. For whole blood applications, integrated blood separation membranes retain red blood cells and permit plasma migration into the membrane, improving flow consistency and reducing cellular interference, although plasma yield will still vary with haematocrit and must be considered during design.

  
  

Each of these strategies must be balanced with manufacturability and user workflow considerations to ensure improvements in laboratory performance translate reliably to real world use.

Practical Evaluation Strategies

Even with carefully optimised assay design, residual variability will remain. Matrix effects, user handling differences and pre-analytical variables cannot be fully engineered out; they must be empirically evaluated. Practical evaluation studies therefore serve as the bridge between laboratory optimisation and real world performance, confirming that mitigation strategies are effective under realistic operating conditions.

A structured approach to evaluation should mirror anticipated sources of variability: volume delivery, matrix interference, stability, and potential interferents. Rather than testing only nominal conditions, developers should intentionally challenge the assay using defined extremes to understand its true operating window and guard bands.

Volume and Handling Variability

Volume related variability is frequently underestimated in lateral flow development. Once a target sample volume and delivery mechanism (pipette, dropper, transfer device) are selected, actual delivered volumes should be verified gravimetrically using the intended matrix. Viscous or protein rich samples often behave differently from water or buffer, leading to systematic under or over delivery.

These measurements allow realistic tolerance ranges to be defined, for example ±10% of the intended volume. The assay can then be challenged across this range to assess the impact on signal intensity, flow behaviour and line formation. This establishes whether performance remains within acceptable analytical limits under user variability.

Handling studies should also consider timing differences, such as delayed buffer addition, variable read times or minor deviations in workflow. Understanding how these factors influence signal development helps define acceptable operating instructions and reduces the risk of misinterpretation.

Matrix Effects and Recovery Assessment

Residual matrix interference should be systematically assessed using spike and recovery experiments. Comparing recovery in buffer versus native matrix allows quantification of signal suppression or enhancement. Testing neat and diluted samples can further clarify whether observed effects are concentration dependent or driven by matrix composition.

Testing across multiple donors is essential to capture biological variability. Individual differences in protein content, viscosity, endogenous antibodies or ionic strength can meaningfully affect assay behaviour. Evaluating performance across representative donors ensures that optimisation is not biased toward a single matrix profile.

Where performance shifts are observed, correlation with specific matrix characteristics (e.g. pH, protein concentration, haematocrit) can inform additional mitigation strategies. This structured feedback loop between testing and refinement strengthens assay robustness before formal validation studies begin.

Stability and Interference Testing

Sample stability must be evaluated under conditions reflecting intended use, including storage temperature, transport duration and realistic freeze-thaw cycles where applicable. Labile analytes require particular attention, as even modest degradation can disproportionately affect assays operating near the limit of detection.

Interference testing should include both endogenous and exogenous substances. Endogenous interferents may include high protein levels, lipids, haemoglobin or heterophilic antibodies. Exogenous interferents may include medications, preservatives or anticoagulants. These studies help distinguish true cross-reactivity from matrix-driven signal artefacts. Where whole blood is used, anticoagulants such as EDTA, citrate or heparin should be evaluated early to confirm compatibility with antibody binding and signal generation. Identifying sensitivity to specific additives prevents unexpected performance shifts during later stage validation.

Integrating Design and Verification

These evaluations are most powerful when used iteratively to refine design decisions. Effective assay development links mitigation and verification rather than treating them as separate activities. Design decisions including membrane selection, buffer formulation or controlled dilution should be confirmed through structured challenge studies under defined variability. Documenting these evaluations supports traceability and demonstrates systematic risk control. More importantly, it ensures that performance achieved during development translates into consistent and reliable results.

Sample Collection, Handling and Stability

The integrity of a sample is a critical determinant of lateral flow assay performance. Delays between collection and testing, exposure to variable temperatures, repeated freeze–thaw cycles or interactions with container materials can degrade analytes. Even minor losses can significantly impact results, particularly for low-concentration targets.

Maintaining stability begins with careful selection of collection and storage materials. Low-protein binding plastics (e.g. polypropylene) minimise adsorption, while secure closures prevent evaporation or contamination. Container design, including surface area to volume ratio and pre-treatment to reduce leachables or reactive surfaces, can further protect analyte integrity.

Consistent handling from collection to testing is equally important. Samples should be processed promptly, stored under defined conditions and protected from extreme temperatures, light or reactive surfaces. For matrices likely to settle or separate, gentle mixing or homogenisation prior to analysis can help ensure analyte uniformity. Where aliquoting is required for batch testing, minimising adsorption and maintaining consistent handling across all aliquots supports reproducibility.

Freeze-thaw cycles should be minimised and, where unavoidable, evaluated using defined cycles that reflect anticipated handling and transport scenarios. Temperature excursions during storage or shipment can accelerate analyte degradation or alter matrix characteristics, so acceptable time–temperature limits should be established experimentally rather than assumed. This is particularly important for decentralised or point-of-care applications, where environmental control may be limited.

Stability should be confirmed using representative specimens under conditions aligned with intended workflows. Defined timepoints, storage temperatures and freeze–thaw exposures should reflect realistic collection, transport and testing pathways.

Matrix specific mechanisms of instability must also be considered. Whole blood may undergo haemolysis, releasing intracellular components that affect signal development. Urine can experience crystallisation or microbial proliferation, altering composition over time. Saliva contains endogenous enzymes that may degrade susceptible analytes unless stabilised or processed promptly. Recognising these mechanisms allows targeted mitigation rather than generic storage controls.

By defining and verifying acceptable stability windows, developers ensure that assay performance reflects analytical capability rather than variability introduced during sample handling. Protecting sample integrity is therefore fundamental to consistent and reliable lateral flow assay performance.

Conclusion

Understanding the sample matrix and its effects is critical to the success of lateral flow assays. Variations in viscosity, pH, particulates, proteins and other matrix components can influence analyte detection, flow and signal development. Recognising these factors early allows developers to anticipate challenges, adjust assay design and implement appropriate sample handling and storage procedures to maintain reproducibility and robust performance.

Key takeaways for understanding and mitigating matrix effects:

• Understand the clinical context: Identify target population, sample type and clinical conditions to anticipate how matrix variability may influence results.

  
  

• Characterise the analyte in the matrix: Consider molecular form, stability and interactions with matrix components such as proteins, enzymes or particulates.

  
  

• Anticipate matrix effects: Evaluate viscosity, pH, endogenous proteins and other factors that may alter flow, binding or signal.

  
  

• Mitigate matrix-related challenges: Adjust buffers, sample dilution and pads / membranes to maintain consistent assay performance.

  
  

• Evaluate the assay in realistic matrices: Use spike/recovery, volume handling, stability studies and samples from multiple donors to confirm performance under real-world sample variability.

  
  

• Ensure matrix integrity during handling: Standardise collection, storage and transport to prevent matrix-induced changes that could affect analyte detection.

  
  

Integrating these considerations early improves assay robustness, informs design decisions and supports generation of data that will guide later regulatory performance studies. Designing assays with matrix effects, user variability and practical constraints in mind reduces late-stage optimisation and increases confidence in development outcomes.

In lateral flow assays, the sample is not simply an input, it actively shapes every stage of design, optimisation and testing.

To learn more about Fleet’s LFA development services click here. Contact us today to discuss your project and explore how we can support your LFA development needs.

Get in Touch